Skip to main content

Table 2 Relation of clinicopathological characteristics with presence of CLS among postmenopausal women with invasive breast cancer (n = 83)

From: Relationship between crown-like structures and sex-steroid hormones in breast adipose tissue and serum among postmenopausal breast cancer patients

 

CLS-positive n (%)

CLS-negative n (%)

 

Unadjusted

Adjustedb

Patient characteristic

p valuea

OR

95% CI

OR

95% CI

Age

  

0.30

    

 40–49 years

1 (3.3)

7 (13.0)

 

0.34

0.04–3.20

0.31

0.03–3.12

 50–59 years

8 (26.7)

19 (35.2)

 

Reference

Reference

 60–69 years

12 (40.0)

18 (33.3)

 

1.68

0.55–5.08

1.17

0.35–3.91

 ≥70 years

9 (30.0)

10 (18.5)

 

2.14

0.63–7.26

1.63

0.45–6.00

BMI category

  

0.03

    

 Lean

4 (14)

19 (36)

 

Reference

Reference

 Overweight

13 (43)

23 (43)

 

2.69

0.75–9.61

1.93

0.50–7.40

 Obese

13 (43)

11 (21)

 

5.61

1.46–21.53

4.63

1.08–19.83

Age at menarche

  

0.28

    

 <13 years

9 (31)

10 (19)

 

Reference

Reference

 ≥13 years

20 (69)

43 (81)

 

0.52

0.18–1.47

0.40

0.12–1.32

Age at menopause

  

0.09

    

 <45 years

2 (7)

6 (11)

 

Reference

Reference

 45–49 years

8 (27)

25 (47)

 

0.96

0.16–5.74

1.50

0.21–10.44

 50–54 years

13 (43)

18 (34)

 

2.17

0.38–12.50

2.95

0.42–20.68

 ≥55 years

7 (23)

4 (8)

 

5.25

0.70–39.48

6.19

0.63–60.73

Age at first birth

  

1.00

    

 Nulliparous

5 (17)

10 (19)

 

Reference

Reference

 <30 years

20 (66)

35 (66)

 

1.14

0.34–3.82

1.08

0.28–4.17

 ≥30 years

5 (17)

8 (15)

 

1.25

0.27–5.89

1.42

0.26–7.93

Family history of breast cancer

  

0.53

    

 No

24 (80)

46 (87)

 

Reference

Reference

 Yes

6 (20)

7 (13)

 

1.64

0.50–5.44

2.91

0.71–11.96

Benign breast disease

  

0.74

    

 No

25 (89)

44 (85)

 

Reference

Reference

 Yes

3 (11)

8 (15)

 

0.66

0.16–2.72

1.09

0.22–5.35

Tumor size

  

1.00

    

 ≤2 cm

15 (52)

26 (49)

 

Reference

Reference

 >2 cm

14 (48)

27 (51)

 

0.90

0.36–2.22

0.62

0.22–1.75

Nodal status

  

0.22

    

 No

20 (67)

26 (49)

 

Reference

Reference

 1–3

7 (23)

15 (28)

 

0.61

0.21–1.77

0.38

0.11–1.41

 ≥4

3 (10)

12 (23)

 

0.33

0.08–1.31

0.44

0.10–2.00

ER status

  

0.80

    

 Positive

21 (70)

39 (74)

 

Reference

Reference

 Negative

9 (30)

14 (26)

 

1.19

0.44–3.22

1.09

0.35–3.39

PR status

  

0.80

    

 Positive

21 (70)

39 (74)

 

Reference

Reference

 Negative

9 (30)

14 (26)

 

1.19

0.44–3.22

1.09

0.35–3.39

Diagnosis

  

0.65

    

 In situ and invasive

17 (57)

33 (62)

 

Reference

Reference

 Invasive only

13 (43)

20 (38)

 

1.26

0.51–3.14

1.22

0.45–3.29

Grade

  

0.70

    

 Well differentiated

4 (13)

11 (21)

 

Reference

Reference

 Moderately differentiated

19 (64)

29 (55)

 

1.80

0.50–6.49

1.32

0.33–5.24

 Poorly differentiated

7 (23)

13 (24)

 

1.48

0.34–6.42

1.68

0.33–8.55

  1. aFisher's exact test. Significant values are shown in bold
  2. bAdjusted for age and BMI (age was adjusted for BMI only, BMI was adjusted for age only) and fat area
  3. BMI body mass index, CI confidence interval, CLS crown-like structures, ER estrogen receptor, OR odds ratio, PR progesterone receptor